Related Experiment Video
Updated: Mar 7, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
Lipoprotein(a) in nephrological patients
1Nephrological Center Villingen-Schwenningen, Albert-Schweitzer-Str. 6, 78052, Villingen-Schwenningen, Germany. hohenstein@nephrologie-vs.de.
Clinical Research in Cardiology Supplements
|February 10, 2017
Summary
Nephrology guidelines lack lipid management recommendations, overlooking lipoprotein(a) (Lp(a)) as a cardiovascular risk factor in chronic kidney disease (CKD) patients. Further evaluation is crucial for appropriate treatment and reducing cardiovascular events.
Area of Science:
- Cardiology
- Nephrology
- Lipidology
Background:
- Existing European Society of Cardiology (ESC) guidelines for lipid disorders contrast sharply with conservative nephrological recommendations.
- Current nephrology guidelines do not address lipoprotein(a) (Lp(a)), a known cardiovascular risk factor, in chronic kidney disease (CKD) management.
- Studies indicate Lp(a) is a significant cardiovascular risk factor, potentially mirroring risks seen in non-CKD patients, especially in stage-3 CKD.
Purpose of the Study:
- To highlight the discrepancy in lipid management guidelines between cardiology and nephrology societies.
- To emphasize the need for incorporating lipoprotein(a) assessment and management into CKD care.
- To advocate for further research into Lp(a)'s role and treatment in CKD patients.
Main Methods:
- Comparative analysis of existing EAS/ESC and nephrological society guidelines.
- Review of retrospective and prospective studies on Lp(a) and cardiovascular risk in CKD.
- Identification of gaps in diagnostic and therapeutic recommendations for Lp(a) in CKD.
Main Results:
- Nephrological guidelines are restrictive regarding lipid-lowering therapy escalation.
- Lipoprotein(a) is omitted from current nephrological recommendations for CKD.
- Lack of guidance on Lp(a) may lead to under-treatment and increased cardiovascular risk in CKD patients.
Conclusions:
- There is a critical need to update nephrological guidelines to include Lp(a) assessment and management.
- Addressing Lp(a) in CKD patients is essential for mitigating cardiovascular event risk.
- Further research is imperative to establish diagnostic and therapeutic protocols for Lp(a) in CKD.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
789
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789
01:26Nephrotic Syndrome II : Assessment and Medical Management
289
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
289
01:24Nephrotic Syndrome III : Nursing Management
402
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
402
01:28Chronic Kidney Disease III: Interprofessional Care
559
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
559
01:30Peripheral Artery Disease I: Introduction
519
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
519
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
420
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
420